

Marijn Mokkai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7024721/publications.pdf>

Version: 2024-02-01

46
papers

405
citations

933447

10
h-index

888059

17
g-index

46
all docs

46
docs citations

46
times ranked

544
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 557-564.	1.9	11
2	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-10.	2.3	1
3	Recurrent Ileal Variceal Bleeding as a Diagnostic and Therapeutic Challenge. <i>Case Reports in Gastrointestinal Medicine</i> , 2022, 2022, 1-4.	0.3	0
4	Does atorvastatin therapy change the anti-Xa activity in dabigatran-treated patients with atrial fibrillation?. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00730.	2.4	5
5	ROTEM Testing for Direct Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 815-823.	2.7	9
6	Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, e122-e127.	1.9	12
7	Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases. <i>Diagnostics</i> , 2021, 11, 143.	2.6	6
8	Impact of Dabigatran Treatment on Rotation Thromboelastometry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962098390.	1.7	8
9	Apixaban. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, e212-e218.	0.9	0
10	Effect of Bisoprolol on the Level of Dabigatran. <i>American Journal of Therapeutics</i> , 2020, 27, e159-e164.	0.9	7
11	The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 333-335.	1.9	9
12	Anti-Xa Activity in Elderly Xabans-Treated Patients With Atrial Fibrillation. <i>American Journal of Therapeutics</i> , 2020, 27, e507-e509.	0.9	3
13	Assessing the hemostasis with thromboelastometry in direct oral anticoagulants-treated patients with atrial fibrillation. <i>Thrombosis Research</i> , 2020, 191, 38-41.	1.7	2
14	Edoxaban affects TRAP-dependent platelet aggregation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 578-583.	2.1	4
15	Anti-Xa Activity-Guided Edoxaban Therapy for Cancer-Associated Venous Thromboembolism?. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.9	1
16	Insulinoma presenting with postprandial hypoglycemia and a low body mass index: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 4169-4176.	0.8	2
17	Severe hypoglycemia due to insulin self-injection as a cause of acute ST elevation myocardial infarction. <i>Journal of Diabetes and Metabolic Disorders</i> , 2019, 18, 739-742.	1.9	3
18	Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?. <i>Pediatric Cardiology</i> , 2019, 40, 1431-1438.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 619-622.	2.1	4
20	Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 846-850.	2.7	14
21	Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 875-877.	1.9	6
22	Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-12.	2.3	7
23	How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation?. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 285-286.	1.9	5
24	Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 140-145.	2.1	10
25	The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. <i>American Journal of Therapeutics</i> , 2019, 26, e308-e313.	0.9	30
26	Therapeutic plasma exchange in secondary prevention of acute pancreatitis in pregnant patient with familial hyperchylomicronemia. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301; Olomouc, Czechoslovakia</i> , 2019, 163, 90-94.	0.6	4
27	First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 914-919.	1.7	11
28	Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?. <i>Diabetes Research and Clinical Practice</i> , 2018, 135, 172-177.	2.8	9
29	Insulin Pump Therapy â€“ Influence on Body Fat Redistribution, Skeletal Muscle Mass and Ghrelin, Leptin Changes in T1D Patients. <i>Obesity Facts</i> , 2018, 11, 454-464.	3.4	3
30	Outcomes of Patients with Newly Diagnosed Cardiac Myxoma: A Retrospective Multicentric Study. <i>BioMed Research International</i> , 2018, 2018, 1-5.	1.9	12
31	First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 393-398.	2.1	10
32	Role of Thromboelastography and Rotational Thromboelastometry in the Management of Cardiovascular Diseases. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1199-1207.	1.7	28
33	Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences. <i>Drugs and Aging</i> , 2018, 35, 539-544.	2.7	10
34	Proton Pump Inhibition in Patients Treated With Novel Antithrombotic Drugs. <i>Journal of Cardiovascular Pharmacology</i> , 2018, 72, 71-76.	1.9	9
35	Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy. <i>Scandinavian Cardiovascular Journal</i> , 2018, 52, 227-231.	1.2	3
36	The role of vaspin as a predictor of coronary angiography result in SCAD (stable coronary artery) Tj ETQq0 0 0 rgBT/Overlock_10 Tf 50 6	1.7	4

#	ARTICLE	IF	CITATIONS
37	Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions. Current Drug Metabolism, 2017, 18, 609-621.	1.2	23
38	Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal. Current Drug Metabolism, 2017, 18, 643-650.	1.2	4
39	The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. Journal of Diabetes Research, 2016, 2016, 1-6.	2.3	2
40	Type 2 Diabetes and ADP Receptor Blocker Therapy. Journal of Diabetes Research, 2016, 2016, 1-7.	2.3	8
41	Endothelial and platelet markers in diabetes mellitus type 2. World Journal of Diabetes, 2015, 6, 423.	3.5	35
42	Waist Circumference as an Independent Risk Factor for NODAT. Annals of Transplantation, 2015, 20, 154-159.	0.9	15
43	Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. American Journal of Emergency Medicine, 2014, 32, 461-465.	1.6	11
44	Prevalence of diabetes mellitus and metabolic syndrome in Slovakia. Diabetes Research and Clinical Practice, 2008, 81, 238-242.	2.8	34
45	Endogenous Digoxin-like Immunoactivity in Subjects With Diabetes Mellitus and Hypertension. American Journal of Hypertension, 1998, 11, 667-676.	2.0	3
46	Sweet's syndrome in a patient with squamous cell carcinoma in terminal of an agnogenic myeloid bone marrow metaplasia. Journal of the European Academy of Dermatology and Venereology, 1997, 8, 55-58.	2.4	0